Eligibility
SCCLG-APL is a randomized, multicenter, and noninferiority trial and was conducted to determine whether intravenous ATO can be substituted by oral RIF in the treatment of pediatric APL 1, which was registered at www.clinicaltrials.gov as NCT02200978. Eligible patients were 16 years old or younger with newly diagnosed APL with confirmation of PML-RARα. Eight of hospitals enrolled in SCCLG-APL participated in present study. The study was approved by institutional review board and informed consent was obtained before treatment in accordance with the Declaration of Helsinki.